IDH2 and neoplasm: Survival analysis of the previously characterized cohort of 58 molecularly and clinical characterized primary IDH-WT glioblastoma (Fig. 5A) revealed shorter progression-free survival in tumors with strong spatial interaction of tumor CD73 and myeloid CD39 relative to tumors with weaker interaction (p = 0.04, Mantel–Cox Long-Rank, Fig. 8J).